Seroba Life Sciences Investments & Fund Profile

Overview

Venture capital firm investing in breakthrough healthcare technologies.

Founded

2009

Deals · 12mo

0

Links

Website LinkedIn

Stage focus

Series A

Series B

Geographic focus

Ireland

Switzerland

The Netherlands

United Kingdom

...

Sector focus

Biotechnology

Financial Services

Health Care

Venture Capital

Investment portfolio

45rounds

LedParticipated

NAME	DATE	SIZE
Azafaros	May 2025Participated	$155 MSeries B
Perfuze	Mar 2025Led	$26 MOther Equity
Coave Therapeutics	Jan 2025Participated	$37 MSeries A
Deciphex	Jan 2025Participated	$36 MSeries C
ShiraTronics	Oct 2024Participated	$66 MSeries B
Loci Orthopaedics	Jul 2024Led	$14 MSeries A
Vico Therapeutics	Jun 2024Led	$12 MSeries B
Artica Therapeutics	Nov 2023Led	$13 MSeed
Shorla Oncology	Oct 2023Participated	$35 MSeries B
Complement Therapeutics	Apr 2023Participated	$79 MSeries A
Deciphex	Jan 2023Led	$4 MSeries B
Storm Therapeutics	Dec 2022Participated	$30 MSeries B
Azafaros	May 2025Participated	$155 MSeries B
Perfuze	Mar 2025Led	$26 MOther Equity
Coave Therapeutics	Jan 2025Participated	$37 MSeries A
Deciphex	Jan 2025Participated	$36 MSeries C
ShiraTronics	Oct 2024Participated	$66 MSeries B
Loci Orthopaedics	Jul 2024Led	$14 MSeries A
Vico Therapeutics	Jun 2024Led	$12 MSeries B
Artica Therapeutics	Nov 2023Led	$13 MSeed
Shorla Oncology	Oct 2023Participated	$35 MSeries B
Complement Therapeutics	Apr 2023Participated	$79 MSeries A
Deciphex	Jan 2023Led	$4 MSeries B
Storm Therapeutics	Dec 2022Participated	$30 MSeries B

45 Items

45

Items

...

Browse all public portfolio deals

Insights

Time horizon

View by

Deal Distribution

Seroba Life Sciences: 45 funding rounds are recorded in the selected participation categories. All available history
Round type	Led deals	Participated deals
Seed	1	0
Series A	6	7
Series B	5	9
Series C+	2	5
Other Equity	5	5

Monthly Deal Activity

Seroba Life Sciences: 45 deals are recorded across 206 months. All available history
Month	Deals
Sep '09	1
Oct '09	0
Nov '09	0
Dec '09	0
Jan '10	0
Feb '10	0
Mar '10	1
Apr '10	0
May '10	0
Jun '10	0
Jul '10	0
Aug '10	0
Sep '10	0
Oct '10	0
Nov '10	1
Dec '10	2
Jan '11	0
Feb '11	1
Mar '11	0
Apr '11	0
May '11	1
Jun '11	0
Jul '11	1
Aug '11	0
Sep '11	0
Oct '11	1
Nov '11	0
Dec '11	1
Jan '12	0
Feb '12	0
Mar '12	0
Apr '12	0
May '12	0
Jun '12	0
Jul '12	0
Aug '12	0
Sep '12	0
Oct '12	0
Nov '12	0
Dec '12	0
Jan '13	0
Feb '13	0
Mar '13	0
Apr '13	1
May '13	0
Jun '13	0
Jul '13	0
Aug '13	0
Sep '13	0
Oct '13	0
Nov '13	0
Dec '13	1
Jan '14	0
Feb '14	0
Mar '14	0
Apr '14	1
May '14	0
Jun '14	0
Jul '14	0
Aug '14	0
Sep '14	0
Oct '14	0
Nov '14	1
Dec '14	0
Jan '15	0
Feb '15	0
Mar '15	0
Apr '15	0
May '15	0
Jun '15	0
Jul '15	0
Aug '15	0
Sep '15	0
Oct '15	0
Nov '15	0
Dec '15	0
Jan '16	0
Feb '16	0
Mar '16	0
Apr '16	0
May '16	0
Jun '16	0
Jul '16	0
Aug '16	0
Sep '16	0
Oct '16	0
Nov '16	0
Dec '16	0
Jan '17	0
Feb '17	1
Mar '17	2
Apr '17	0
May '17	0
Jun '17	0
Jul '17	0
Aug '17	0
Sep '17	1
Oct '17	0
Nov '17	0
Dec '17	0
Jan '18	0
Feb '18	0
Mar '18	0
Apr '18	0
May '18	0
Jun '18	0
Jul '18	0
Aug '18	0
Sep '18	1
Oct '18	0
Nov '18	0
Dec '18	0
Jan '19	2
Feb '19	0
Mar '19	0
Apr '19	2
May '19	1
Jun '19	0
Jul '19	1
Aug '19	0
Sep '19	0
Oct '19	1
Nov '19	0
Dec '19	0
Jan '20	0
Feb '20	0
Mar '20	0
Apr '20	0
May '20	0
Jun '20	1
Jul '20	0
Aug '20	0
Sep '20	0
Oct '20	0
Nov '20	0
Dec '20	0
Jan '21	0
Feb '21	1
Mar '21	0
Apr '21	0
May '21	0
Jun '21	2
Jul '21	1
Aug '21	0
Sep '21	0
Oct '21	0
Nov '21	0
Dec '21	0
Jan '22	0
Feb '22	1
Mar '22	0
Apr '22	0
May '22	0
Jun '22	0
Jul '22	0
Aug '22	0
Sep '22	0
Oct '22	1
Nov '22	0
Dec '22	1
Jan '23	1
Feb '23	0
Mar '23	0
Apr '23	1
May '23	0
Jun '23	0
Jul '23	0
Aug '23	0
Sep '23	0
Oct '23	1
Nov '23	1
Dec '23	0
Jan '24	0
Feb '24	0
Mar '24	0
Apr '24	0
May '24	0
Jun '24	1
Jul '24	1
Aug '24	0
Sep '24	0
Oct '24	1
Nov '24	0
Dec '24	0
Jan '25	2
Feb '25	0
Mar '25	1
Apr '25	0
May '25	1
Jun '25	0
Jul '25	0
Aug '25	0
Sep '25	0
Oct '25	0
Nov '25	0
Dec '25	0
Jan '26	0
Feb '26	0
Mar '26	0
Apr '26	0
May '26	0
Jun '26	0
Jul '26	0
Aug '26	0
Sep '26	0
Oct '26	0

Sector Breakdown

A deal can appear in multiple sectors, so sector totals may overlap. Capital represents disclosed total round sizes, not fund cheque sizes.

Seroba Life Sciences: Health & Life Sciences is the largest displayed sector by deal count (45 deals). All available history
Sector	Deals
Health & Life Sciences	45
Manufacturing	8
Consumer & Lifestyle	3
Networks, Cloud & Communication	2
AI & Machine Learning	2
Space & Frontier Tech	2
Developer Tools	1
Marketing & Advertising	1
Hardware & Robotics	1
Enterprise Software	1
Media & Entertainment	1

Deal Size Distribution

Undisclosed round sizes are excluded. Capital represents total round sizes, not fund cheque sizes.

Seroba Life Sciences: 45 rounds have a disclosed size in the displayed size bands. All available history
Round size band (USD)	Deals
<$5M	4
$5M-$10M	7
$10M-$25M	11
$25M-$50M	15
$50M-$100M	4
$100M-$250M	4
$250M-$500M	0
$500M-$1B	0
$1B+	0

Deals By Geography

Top 3 of 3 regions; European countries are grouped as Europe.

Seroba Life Sciences: Europe has the largest recorded deal count among the displayed regions (36 deals). All available history
Region	Deals
Europe	36
United States	7
Canada	2

Co-Investors

Bubble size = shared deals

Click a bubble to open that fund in a new tab.

Shows up to 20 co-investors ranked by shared deals. Deals may be shared with multiple funds, so rows overlap. Capital is total round size, not fund cheque size.

Seroba Life Sciences: 20 co-investors are shown, with EQT Life Sciences (LSP) sharing 5 recorded deals. All available history
Co-investor	Shared deals
EQT Life Sciences (LSP)	5
Forbion	5
btov Partners	4
Johnson & Johnson Innovation	4
Kurma Partners	4
SV Health Investors	4
Wellington Partners	4
Act Venture Capital	3
Adams Street Partners	3
Aperture Venture Partners	3
Atlantic Bridge	3
BioGeneration Ventures	3
Earlybird	3
Edmond de Rothschild Investment Partners	3
Enterprise Ireland	3
FACIT	3
Genesys Capital	3
HealthCap	3
M Ventures	3
Novartis	3